T-Cell Repertoire in Tumor Radiation: The Emerging Frontier as a Radiotherapy Biomarker

Cancers

Maria Adamaki¹  Vassilios Zoumpourlis¹  Sotirios P. Fortis²  Maria Goulielmaki²  Ioannis F. Voutsas²  Constantin N. Baxevanis²  Panagiota Batsaki²  Angelos D. Gritzapis² 

[1] Biomedical Applications Unit, Institute of Chemical Biology, National Hellenic Research Foundation (NHRF), 11635 Athens, Greece;Cancer Immunology and Immunotherapy Center, Saint Savas Cancer Hospital, 11522 Athens, Greece;

关键词: radiotherapy;    biomarkers;    immunotherapy;    cancer;    abscopal effect;    TCR repertoire;   

DOI  :  10.3390/cancers14112674

来源: DOAJ

【 摘 要 】

Radiotherapy (RT) is a therapeutic modality that aims to eliminate malignant cells through the induction of DNA damage in the irradiated tumor site. In addition to its cytotoxic properties, RT also induces mechanisms that result in the promotion of antitumor immunity both locally within the irradiation field but also at distant tumor lesions, a phenomenon that is known as the “abscopal” effect. Because the immune system is capable of sensing the effects of RT, several treatment protocols have been assessing the synergistic role of radiotherapy combined with immunotherapy, collectively referred to as radioimmunotherapy. Herein, we discuss mechanistic insights underlying RT-based immunomodulation, which also enhance our understanding of how RT regulates antitumor T-cell-mediated immunity. Such knowledge is essential for the discovery of predictive biomarkers and for the improvement of clinical trials investigating the efficacy of radio-immunotherapeutic modalities in cancer patients.

【 授权许可】

Unknown